MedWorm: Abilify

Clinical use of aripiprazole in patients with schizophrenia: A real-life setting results from the German Postmarketing Surveillance Study.

The World Journal of Biological Psychiatry — Sun, 14 Mar 2010 04:40:03 +0100

Authors: Messer T, Schmauß M, Spevakne-Goeroecs T, Kungel M, Ebrecht M, Werner C, Modell S When aripiprazole (ABILIFY(R)) received its approval in Germany for the treatment of schizophrenia, a hospital-based postmarketing surveillance study was initiated in order to gain further insights concerning safety and efficacy of the antipsychotic under real-life conditions. Efficacy was rated by using standard CGI, GAF, and SF-12 instruments, whereas safety was evaluated according to the reports on adverse effects. Data from 799 patients with schizophrenia from 122 psychiatric hospitals returned for evaluation. Eighty percent of the patients were treated for 4 weeks with 10-30 mg/day aripiprazole (mean modal dose 15 mg/day). Within the observation period significant improvements of CGI, G...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

A Pilot, 15-month, randomised effectiveness trial of Risperidone long-acting injection (RLAI) versus oral atypical antipsychotic agents (AAP) in persons with bipolar disorder

Acta Neuropsychiatrica — Thu, 11 Mar 2010 00:00:00 +0100

Conclusions: RLAI-treated patients experienced significantly fewer negative clinical events. Further exploration should focus on which subtypes of BPD patients might benefit from RLAI treatment. Weight gain in BPD subjects requires clinical attention. Limitations include an open design, small sample size and the inability to conclude on whether this strategy is useful for depressive episodes. (Source: Acta Neuropsychiatrica)

Symptomatic Bradycardia with Oral Aripiprazole and Oral Ziprasidone (April).

The Annals of Pharmacotherapy — Tue, 09 Mar 2010 00:00:00 +0100

CONCLUSIONS: Further studies are needed to better determine the relationship between antipsychotics and reflex bradycardia. Although bradycardia remains a relatively uncommon phenomenon seen with the use of these medications, the severity of this potential adverse effect warrants consideration when initiating antipsychotic therapy. PMID: 20215494 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)

Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors

Annals of General Psychiatry — Sat, 06 Mar 2010 00:00:00 +0100

Conclusion: Doctors may wish to consider fluvoxamine as an alternative approach in treating akathisia associated with antipsychotic drugs such as aripiprazole. (Source: Annals of General Psychiatry)

Differential Effects of Various Typical and Atypical Antipsychotics on Plasma Glucose and Insulin Levels in the Mouse: Evidence for the Involvement of Sympathetic Regulation

Schizophrenia Bulletin — Fri, 05 Mar 2010 19:18:36 +0100

Atypical antipsychotic treatment has been associated with serious metabolic adverse events, such as glucose dysregulation and development of type 2 diabetes. As part of our studies on possible underlying mechanisms, we investigated the acute effects of various typical and atypical antipsychotics on plasma glucose and insulin in FVB/N mice, a strain that showed a more pronounced hyperglycemic response to clozapine than C57BL/6 and CD-1 mice. Acute administration of high doses of clozapine, olanzapine, quetiapine, perphenazine, or chlorpromazine significantly increased plasma glucose by 100%–140% above basal levels without significant effects on insulin levels. In contrast, risperidone reduced plasma glucose (–30%) and markedly enhanced plasma insulin levels. Doses of ziprasidone...

Aripiprazole-induced rabbit syndrome: a case report

Journal of Psychopharmacology — Fri, 05 Mar 2010 12:53:19 +0100

We present the case of a patient who developed RS during treatment with aripiprazole. Potential mechanisms, including D2 receptor occupancy, low anticholinergic properties and dopamine hypersensitivity theory, are discussed. Although studies with aripiprazole have shown a low liability for extrapyramidal side effects, the present case emphasises the need for caution when treating patients with aripiprazole. (Source: Journal of Psychopharmacology)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Aripiprazole for the maintenance treatment of bipolar I disorder: A review.

Clinical Therapeutics — Fri, 05 Mar 2010 04:06:03 +0100

CONCLUSIONS: The available evidence supports the efficacy and tolerability of aripiprazole in the maintenance treatment of bipolar disorder. The placebo-subtracted differences in body composition and metabolic parameters suggest utility for aripiprazole in the long-term treatment of bipolar disorder. PMID: 20152551 [PubMed - in process] (Source: Clinical Therapeutics)

Aripiprazole in schizophrenia and schizoaffective disorder: A review.

Clinical Therapeutics — Fri, 05 Mar 2010 04:06:03 +0100

CONCLUSIONS: Based on the evidence reviewed, aripiprazole monotherapy appears to be effective and well tolerated in treating the positive, negative, and cognitive symptoms of schizophrenia and schizoaffective disorder. It was associated with a low risk for the common adverse effects of antipsychotic therapy, including metabolic and endocrine alterations. PMID: 20152550 [PubMed - in process] (Source: Clinical Therapeutics)

The role of aripiprazole in Canada: A review of clinical and drug discontinuation data. Foreword.

Clinical Therapeutics — Fri, 05 Mar 2010 04:06:03 +0100

Authors: McIntyre RS PMID: 20152548 [PubMed - in process] (Source: Clinical Therapeutics)

Aripiprazole/risperidone: Parkinsonism: case report

Reactions — Mon, 01 Mar 2010 14:50:10 +0100

(Source: Reactions)

Neurocognition and its influencing factors in the treatment of schizophrenia - effects of aripiprazole, olanzapine, quetiapine and risperidone

Human Psychopharmacology: Clinical and Experimental — Mon, 01 Mar 2010 00:00:00 +0100

To examine influencing variables of neurocognition in patients with schizophrenia and to predict cognition during antipsychotic treatment.Data were obtained from patients with an acute episode of schizophrenia participating in two double-blind and one open label trial comparing the effects of different atypical antipsychotics on cognition. In total, 129 patients were enrolled in this analysis. Cognitive function was assessed at admission, week 4 and 8. Efficacy and tolerability were assessed weekly using the Positive and Negative Syndrome Scale (PANSS) and the Simpson Angus Sale (SAS). Patients were treated with aripirazole, olanzapine, quetiapine and risperidone. Regression analysis including mixed effect models was performed.A significant improvement in all cognitive domains was observed...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study

Human Psychopharmacology: Clinical and Experimental — Mon, 01 Mar 2010 00:00:00 +0100

The use of atypical antipsychotics (AAPs) for the treatment of unipolar and bipolar depression has been more and more frequently evaluated, and aripiprazole showed positive effects in the treatment of unipolar depression. However, no placebo-controlled studies of adjunctive aripiprazole for the treatment of bipolar depression have been performed yet.In this prospective, double-blind, placebo-controlled, randomized trial, 23 inpatients with bipolar depression according to DSM-IV criteria were included. Before randomization, patients had to be on a constant mood stabilizer treatment with lithium or valproate for at least 1 week. After inclusion, all patients were openly treated with additional citalopram and with additional aripiprazole or placebo for 6 weeks. The primary outcome parameter w...

Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004

Human Psychopharmacology: Clinical and Experimental — Mon, 01 Mar 2010 00:00:00 +0100

We tested the hypothesis that combinations and total daily doses of psychotropics for hospitalized patients diagnosed with major psychiatric disorders are rising.We evaluated McLean Hospital records of 481 consecutive inpatients with DSM-IV schizophrenia, schizoaffective, or bipolar disorders in 2004 (n = 278) or 2009 (n = 203) to compare characteristics and treatments.In 2009, Clinical Global Impression (CGI)-severity scores were 6% lower at intake and improved 1.7 times more than in 2004, as hospitalization-length decreased by 12%. Polytherapy ([ge] 2 psychotropics) increased in 2009 (affective or schizoaffective disorders > schizophrenia). Total psychotropics/patient (3.1-3.2) remained stable but mood-stabilizers/patient increased markedly and antipsychotics/patient decreased somewhat i...

Aripiprazole: a drug with a novel mechanism of action and possible efficacy for alcohol dependence.

CNS and Neurological Disorders Drug Targets — Mon, 01 Mar 2010 00:00:00 +0100

This article proposes a potential role for aripiprazole in alcoholism treatment, and suggests that more randomized controlled trials should be designed at appropriate doses to better understand aripiprazole's potential role as a treatment option. More options are needed to treat alcoholics that fall into different subgroups (e.g., those with impulsive disorders), or non-responsive to available treatments. Early results with aripiprazole are promising and warrant further exploration. PMID: 20201815 [PubMed - in process] (Source: CNS and Neurological Disorders Drug Targets)

Favourable results in treatment-resistant schizophrenic patients under combination of aripiprazole with clozapine.

The World Journal of Biological Psychiatry — Mon, 01 Mar 2010 00:00:00 +0100

We report the case of four patients in whom we observed a distinct clinical improvement with respect to positive and negative symptoms without major side effects under a combination of clozapine and aripiprazole. The combination of clozapine action and aripiprazole-mediated D(2) receptor regulation could be responsible for the described favourable effects and for the increase of D(2) receptor blockade after adding aripiprazole to clozapine observed in one patient. A combination of clozapine and aripiprazole may be an effective therapeutic strategy for some schizophrenic patients, leading to a good response with respect to positive and negative symptoms without the occurrence of major side effects. PMID: 20218805 [PubMed - in process] (Source: The World Journal of Biological Psychiatry)

Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients.

The World Journal of Biological Psychiatry — Mon, 01 Mar 2010 00:00:00 +0100

Authors: Yoshimura R, Ueda N, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Nakamura J In the present study, we longitudinally investigated the effects of risperidone, olanzapine, and aripiprazole on plasma levels of catecholamine metabolites and brain-derived neurotrophic factor (BDNF) in first-episode unmedicated schizophrenic patients. The subjects were 59 Japanese schizophrenic patients (35 males and 24 females; age range: 18-46 years; mean+/-SD: 25+/-16 years). The patients were treated with risperidone (n=32) in a dose range of 2-6 mg/day (mean+/-SD=3.4+/-1.9), olanzapine (n=18) in a dose range of 5-20 mg/day (mean+/-SD=12.1+/-5.8), or aripiprazole (n=9) in a dose range of 12-30 mg/day (mean+/-SD=22.8+/-10.1). All three drugs significantly decreased plasma homovanillic acid (HVA) l...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Pathological gambling and compulsive eating associated with aripiprazole.

The Australian and New Zealand Journal of Psychiatry — Sat, 27 Feb 2010 05:10:13 +0100

Authors: Roxanas MG PMID: 20180730 [PubMed - in process] (Source: The Australian and New Zealand Journal of Psychiatry)

Aripiprazole effective in treatment of irritability in children with autism [HEALTH BRIEFS]

AAP News — Fri, 26 Feb 2010 18:01:27 +0100

(Source: AAP News)

Treating Irritability in Children and Adolescents With Autism

Medscape Today Headlines — Fri, 26 Feb 2010 17:00:10 +0100

Valuable randomized trial data for physicians and families who are considering placing an autistic child on aripiprazole. Medscape Pediatrics (Source: Medscape Today Headlines)

Identification of Molecular Targets Associated With Ethanol Toxicity and Implications in Drug Development.

Current Pharmaceutical Design — Thu, 25 Feb 2010 00:00:00 +0100

In this study, we have examined the molecular targets of ethanol-induced toxicity in humans based on a systematic review of literature data and then discussed current and potential therapeutic targets for alcohol abuse and dependence. Using human samples with ethanol exposure, microarray analyses of gene expression have shown that numerous genes are up- and/or down-regulated by alcohol exposure. The ethanol-responsive genes mainly encode functional proteins such as proteins involved in nucleic acid binding, transcription factors, selected regulatory molecules, and receptors. These genes are also correlated with important biological pathways, such as angiogenesis, integrin signalling pathway, inflammation, wnt signaling pathway, platelet-derived growth factor signaling pathway, p53 pathway,...

Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature

Archives of Women's Mental Health — Wed, 24 Feb 2010 06:49:45 +0100

Abstract Hyperprolactinemia, an adverse side-effect of the use of typical and some atypical antipsychotics, has both acute and chronic clinical consequences. When observed in schizophrenic patients, it may be treated by switching the patient to an antipsychotic agent with a lower liability for the induction of hyperprolactinemia. The effects of substituting aripiprazole for other antipsychotic agents on schizophrenic patients with antipsychotic-induced hyperprolactinemia have been previously reported in several studies. Many studies have also noted that aripiprazole can sometimes lead to increases in psychotic symptoms, especially in the period immediately following the switch or when aripiprazole is combined with a dopamine antagonist. Here, we report observations on five...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in Japanese chronic schizophrenia

Psychopharmacology — Tue, 23 Feb 2010 07:17:23 +0100

Conclusion Aripiprazole and risperidone may improve PPI90. ASR, HAB, PPI82, and PPI86 were no different among the Japanese schizophrenic patient groups with different antipsychotics. Content Type Journal ArticleCategory Original InvestigationDOI 10.1007/s00213-010-1787-xAuthors Taro Kishi, Fujita Health University School of Medicine Department of Psychiatry Toyoake Aichi 470-1192 JapanMasatsugu Moriwaki, Fujita Health University School of Medicine Department of Psychiatry Toyoake Aichi 470-1192 JapanTsuyoshi Kitajima, Fujita Health University School of Medicine Department of Psychiatry Toyoake Aichi 470-1192 JapanKunihiro Kawashima, Fujita Health University School of Medicine Department of Psychiatry Toyoake Aichi 470-1192 JapanTomo Okochi, Fujita Health University S...

Aripiprazole in anorexia nervosa and low-weight bulimia nervosa: Case reports

International Journal of Eating Disorders — Mon, 22 Feb 2010 00:00:00 +0100

We report on the treatment of eight patients (five with AN and three with BN) with aripiprazole for time periods of four months to more than three years.All individuals had reduced distress around eating, fewer obsessional thoughts about food, weight and body image, significant lessening of eating-disordered behaviors, and gradual weight restoration where appropriate. Depression, generalized anxiety, and cognitive flexibility improved as well.In summary, these findings support the need to perform controlled trials of aripiprazole in AN and BN. © 2010 by Wiley Periodicals, Inc. Int J Eat Disord 2010 (Source: International Journal of Eating Disorders)

Changes in Positive and Negative Syndrome Scale–Derived Hostility Factor in Adolescents with Schizophrenia Treated with Aripiprazole: Post Hoc Analysis of Randomized Clinical Trial Data

Journal of Child and Adolescent Psychopharmacology — Thu, 18 Feb 2010 13:08:25 +0100

Journal of Child and Adolescent Psychopharmacology Feb 2010, Vol. 20, No. 1: 33-38. (Source: Journal of Child and Adolescent Psychopharmacology)

Predictors of Early Worsening after Switch to Aripiprazole: A Randomized, Controlled, Open-Label Study

Clinical Drug Investigation — Wed, 17 Feb 2010 14:10:10 +0100

(Source: Clinical Drug Investigation)

Aripiprazole, Hypertension, and Confusion [LETTERS TO THE EDITOR]

J Neuropsychiatry Clin Neurosci — Tue, 16 Feb 2010 20:34:00 +0100

(Source: J Neuropsychiatry Clin Neurosci)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Coping with Atypical Antipsychotic Side Effects

Psych Central — Wed, 10 Feb 2010 22:41:14 +0100

Atypical antipsychotics are widely believed to be better tolerated in adults than first-generation, or typical antipsychotics, and more likely to be taken long-term. They are less likely to cause tremors and other serious movement disorders that affect users of typical antipsychotics. In contrast to the earlier drugs, atypicals usually work on serotonin receptors in addition to dopamine receptors. Drugs in this group include olanzapine (Zyprexa), clozapine (Clozaril), risperidone (Risperdal), quetiapine (Seroquel), ziprasidone (Geodon), aripiprazole (Abilify) and paliperidone (Invega). The drugs are prescribed for conditions such as schizophrenia and bipolar disorders and may also be given for agitation, anxiety, psychotic episodes and obsessive behaviors. Their off-label use is increasin...

Alkermes Unveils Long-Acting Injectable Proprietary Platform For Treatment Of Schizophrenia And Other CNS Disorders

Health News from Medical News Today — Sun, 07 Feb 2010 08:00:00 +0100

Alkermes, Inc. (NASDAQ: ALKS) announced that it has developed a novel, proprietary LinkeRx™ technology platform to enable the creation of injectable extended-release versions of antipsychotics and other central nervous system (CNS) therapies. The company's lead candidate that leverages this platform, designated as ALKS 9070, is a once-monthly, injectable, extended-release version of aripiprazole for the treatment of schizophrenia. Aripiprazole is commercially available under the name ABILIFY® for the treatment of a number of CNS disorders... (Source: Health News from Medical News Today)

Cochrane review: Zotepine versus other atypical antipsychotics for schizophrenia

NeLM - Drug Specific Reviews — Tue, 02 Feb 2010 00:00:00 +0100

Source: Cochrane Library Area: Evidence > Drug Specific Reviews Background In many countries of the industrialised world, second generation (atypical) antipsychotic drugs have become first line treatment for people with schizophrenia. The question as to whether the effects of various second generation antipsychotic drugs differ is a matter of debate. In this review we examined how the efficacy and tolerability of zotepine differs from that of other second generation antipsychotic drugs. Objectives To evaluate the effects of zotepine compared with other second generation antipsychotic drugs for people with schizophrenia and schizophrenia-like psychoses. Search strategy We searched the Cochrane Schizophrenia Group Trials Register (April 2007) which is based on regula...

Cochrane review: Quetiapine versus other atypical antipsychotics for schizophrenia

NeLM - Drug Class Focused Reviews — Tue, 02 Feb 2010 00:00:00 +0100

Source: Cochrane Library Area: Evidence > Drug Class Focused Reviews Background In many countries of the industrialised world second generation ('atypical') antipsychotic drugs have become the first line drug treatment for people with schizophrenia. It is not clear how the effects of the various second generation antipsychotic drugs differ. Objectives To evaluate the effects of quetiapine compared with other second generation antipsychotic drugs for people with schizophrenia and schizophrenia-like psychosis. Search strategy We searched the Cochrane Schizophrenia Group Trials Register (April 2007), inspected references of all identified studies, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. ...

Evidence-Based Use of Second-Generation Antipsychotics in a State Medicaid Pediatric Population, 2001-2005 [Articles]

Psychiatr Serv — Mon, 01 Feb 2010 13:01:21 +0100

CONCLUSIONS: The number of children receiving second-generation antipsychotics doubled in this Medicaid population between 2001 and 2005, and a large proportion of the treatments were not supported by evidence from clinical studies. (Source: Psychiatr Serv)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Use of aripiprazole in clozapine induced enuresis: report of two cases.

J Korean Med Sci — Mon, 01 Feb 2010 00:00:00 +0100

This report describes the efficacy of combined use of aripiprazole in the treatment of a patient with clozapine induced enuresis. Aripiprazole acts as a potential dopamine partial agonist and the dopamine blockade in the basal ganglia might be one of the causes of urinary incontinence and enuresis. We speculate that aripiprazole functioned as a D2 agonist in hypodopaminergic state of basal ganglia caused by clozapine and maintained dopamine level that would improve enuresis ultimately. PMID: 20119596 [PubMed - in process] (Source: J Korean Med Sci)

Aripiprazole: Movement disorders: 6 case reports

Reactions — Wed, 27 Jan 2010 14:05:47 +0100

(Source: Reactions)

Amisulpride versus other atypical antipsychotics for schizophrenia

NeLM - Mental Health — Tue, 26 Jan 2010 00:00:00 +0100

Source: Cochrane Library Area: Evidence > Drug Class Focused Reviews Background In many countries of the industrialised world second generation (atypical) antipsychotics have become first line drug treatments for people with schizophrenia. The question as to whether, and if so how much, the effects of the various second generation antipsychotics differ is a matter of debate. In this review we examine how the efficacy and tolerability of amisulpride differs from that of other second generation antipsychotics. Objectives To evaluate the effects of amisulpride compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. Search strategy We searched the Cochrane Schizophrenia Group Trials Register (April 2007) which is based ...

The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior.

Behavioural Brain Research — Thu, 21 Jan 2010 00:00:00 +0100

Authors: Sarkisyan G, Roberts AJ, Hedlund PB The 5-HT(7) receptor has been suggested as a target for treating depression since inactivation or blockade of the receptor has an antidepressant-like behavioral effect. The present study investigated possible interactions between various classes of drugs with antidepressant properties and blockade or inactivation of the 5-HT(7) receptor. Immobility despair in the tail suspension test and the forced swim test was evaluated in mice lacking the 5-HT(7) receptor (5-HT(7)(-/-)) and in wild-type controls (5-HT(7)(+/+)) following acute drug treatments. Citalopram, a selective serotonin reuptake inhibitor and widely used antidepressant, dose-dependently reduced immobility in the tail suspension test in both 5-HT(7)(+/+) and 5-HT(7)(-/-) mice. Combin...

Identification of Selected Therapeutic Agents as Inhibitors of Carboxylesterase 1: Potential Sources of Metabolic Drug Interactions.

Toxicology — Thu, 21 Jan 2010 00:00:00 +0100

In conclusion, drug-drug interactions with MPH are likely mediated via CES1 inhibition as a result of concomitant drug therapies. CES1 inhibition represents an overlooked and little studied source of variability in MPH disposition, tolerability, and response. PMID: 20097249 [PubMed - as supplied by publisher] (Source: Toxicology)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Trial of aripiprazole in the treatment of first-episode schizophrenia

Psychiatry and Clinical Neurosciences — Wed, 20 Jan 2010 00:00:00 +0100

Conclusions: Aripiprazole is an effective and well-tolerated antipsychotic agent in patients with first-episode schizophrenia. Further investigations with larger samples are needed. (Source: Psychiatry and Clinical Neurosciences)

Effectiveness of aripiprazole in a patient with presumed idiopathic Parkinson's disease and chronic paranoid schizophrenia

Psychiatry and Clinical Neurosciences — Wed, 20 Jan 2010 00:00:00 +0100

(Source: Psychiatry and Clinical Neurosciences)

Aripiprazole: Paroxysmal supraventricular tachycardia: case report

Reactions — Tue, 19 Jan 2010 14:09:29 +0100

(Source: Reactions)

Aripiprazole: Acute dystonia: case report

Reactions — Tue, 19 Jan 2010 14:09:29 +0100

(Source: Reactions)

Risperidone: Hyperprolactinaemia attenuated with aripiprazole: case report

Reactions — Tue, 19 Jan 2010 14:09:29 +0100

(Source: Reactions)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

EMEA publishes questions and answers on the withdrawal of application for a change to the marketing authorisation for aripiprazole (AbilifyT)

NeLM - Mental Health — Wed, 06 Jan 2010 00:00:00 +0100

Source: EMEA Area: News The EMEA has published a questions and answers document explaining the reasons behind the withdrawal of the application for a new indication for aripiprazole (AbilifyT) in the treatment of resistant major depressive episodes. The withdrawal was based on the Committee for Medicinal Products for Human Use (CHMP) consideration that there were insufficient long term data to support this indication. (Source: NeLM - Mental Health)

The risk of death among adult participants in trials of antipsychotic drugs in schizophrenia1

European Neuropsychopharmacology — Wed, 06 Jan 2010 00:00:00 +0100

Abstract: In this paper we investigate mortality in short-term placebo-controlled trials conducted to demonstrate efficacy and safety of atypical antipsychotic drugs for the treatment of schizophrenic patients in the acute phase of illness. Arguments are provided, why short-term placebo-controlled studies are required.This is an integrated analysis of results from randomized placebo-controlled trials conducted pre-licensing for risperidone, olanzapine, quetiapine IR, ziprasidone, risperidone consta, aripiprazole, paliperidone, and quetiapine XR. Information was retrieved from study publications, EPAR, and from the FDA SBA, all in the public domain.7553 patients were randomized in the remaining 23 short-term acute phase clinical trials. 2/5738 patients died after having been randomized to a...

The Brown University Psychopharmacology Update — Tue, 05 Jan 2010 16:26:26 +0100

Antidepressants Plus Psychotherapy no More Effective for Chronic DepressionReview of MRI Studies Evaluates Impact of Antipsychotics on Brain StructureMyxedema Coma Secondary to Aripiprazole and SertralineMemantine Add-On to Clozapine for Treatment-Refractory SchizophreniaWhen Received Wisdom Fails: Psychotherapy for Treatment-Resistant DepressionEffects of Antipsychotics on Brain StructureOpen-Label Study of Escitalopram for OCDAripiprazole as Add-On to Risperidone or Quetiapine for SchizophreniaVocal Tics with ZiprasidoneApprovals: Seroquel XR as Add-On Treatment to Antidepressants in MDDApprovals: Seroquel for Pediatric Schizophrenia and Bipolar I DisorderApprovals: Zyprexa for Schizophrenia and Bipolar I Disorder in Adolescents (Source: The Brown University Psychopharmacology Update)

Metabolic Testing Rates in 3 State Medicaid Programs After FDA Warnings and ADA/APA Recommendations for Second-Generation Antipsychotic Drugs [Original Article]

Archives of General Psychiatry — Mon, 04 Jan 2010 20:51:26 +0100

Conclusions In a Medicaid-receiving population, baseline glucose and lipid testing for SGA-treated patients was infrequent and showed little change following the diabetes warning and monitoring recommendations. A change in SGA drug selection consistent with intentions to reduce metabolic risk was observed. (Source: Archives of General Psychiatry)

Short Course of Atypicals Led to Rapid Weight Gain

Clinical Psychiatry News — Fri, 01 Jan 2010 00:00:00 +0100

Children and adolescents rapidly gain substantial weight on a short course of the atypical antipsychotic medications aripiprazole, olanzapine, quetiapine, and risperidone, according to a report in the JAMA. (Source: Clinical Psychiatry News)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Aripiprazole OK'd for Autism-Related Irritability

Pediatric News — Fri, 01 Jan 2010 00:00:00 +0100

The atypical antipsychotic aripiprazole has been approved for treating irritability associated with autistic disorder in children and adolescents aged 6–17 years. Irritability includes symptoms of aggression toward others, deliberate self-injuriousness, temper tantrums, and quickly changing moods, the manufacturers said. (Source: Pediatric News)

Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials [REVIEW ARTICLES]

The British Journal of Psychiatry — Thu, 31 Dec 2009 23:31:26 +0100

Conclusions The current evidence from randomised controlled trials suggests that drug treatment, especially with mood stabilisers and second-generation antipsychotics, may be effective for treating a number of core symptoms and associated psychopathology, but the evidence does not currently support effectiveness for overall severity of borderline personality disorder. Pharmacotherapy should therefore be targeted at specific symptoms. (Source: The British Journal of Psychiatry)

Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis

Annals of General Psychiatry — Thu, 31 Dec 2009 00:00:00 +0100

Conclusion: The data analysed for the current study support the usefulness of aripiprazole against psychotic symptoms during the acute manic and maintenance phases of bipolar illness. (Source: Annals of General Psychiatry)

Aripiprazole in Children and Adolescents with Tourette's Disorder: An Open-Label Safety and Tolerability Study

Journal of Child and Adolescent Psychopharmacology — Sat, 26 Dec 2009 22:17:47 +0100

Journal of Child and Adolescent Psychopharmacology Dec 2009, Vol. 19, No. 6: 623-633. (Source: Journal of Child and Adolescent Psychopharmacology)

Co-operativity in agonist binding at the D2 dopamine receptor: evidence from agonist dissociation kinetics

Journal of Neurochemistry — Thu, 24 Dec 2009 00:00:00 +0100

J. Neurochem. (2010) 10.1111/j.1471-4159.2009.06554.x There is much evidence to suggest that G protein coupled receptors exist as oligomers but the relevance to their function is unclear. We have, therefore, examined the binding of the radiolabelled agonist [3H]NPA to membranes of CHO cells expressing the D2 dopamine receptor in dissociation rate experiments. When [3H]NPA dissociation was started by dilution, the dissociation rate in the absence of sodium ions was unaffected by addition of the antagonist/inverse agonist (+)-butaclamol, but was accelerated by addition of agonists e.g. dopamine, suggesting that the receptor was not behaving as a monomer with a single binding site. The very low efficacy partial agonist, aripiprazole provided an intermediate level of acceleration of dissociati...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

The effect of dopamine partial agonists on the nicotine dependency in patients with schizophrenia

Human Psychopharmacology: Clinical and Experimental — Wed, 23 Dec 2009 00:00:00 +0100

We compared the effects of haloperidol and three atypical antipsychotics (risperidone, olanzapine, and aripiprazole) on nicotine dependence in schizophrenic patients.One hundred and thirty nine schizophrenic patients, who began using antipsychotic medication, were assessed for severity of nicotine dependence and for cigarette craving at baseline and following 8 weeks of treatment using the Fagerström Tolerance Questionnaire (FTQ) and a Likert-style, seven point, visual-analogue rating scale.Nicotine dependence increased in the haloperidol group, but not in atypical antipsychotics groups. Patients treated with aripiprazole showed a reduction both in nicotine dependence and cigarette craving.The effects of aripiprazole, a partial agonist of the dopamine D2 receptor, may reduce the severity ...

Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: A post-hoc, pooled analysis of two large, placebo-controlled studies

Journal of Affective Disorders — Tue, 15 Dec 2009 14:42:25 +0100

The objective of this study was to examine the effects of aripiprazole on core symptoms of depression.Methods: This is a post-hoc, pooled analysis of two trials of aripiprazole augmentation of standard antidepressants (ADT) in patients with major depression. Patients with an inadequate response to ADT received adjunctive aripiprazole (n=373) or placebo (n=368) for 6weeks. Change on four subscales of the 17-item Hamilton Depression Rating Scale (HAM-D17) that capture core depression symptoms was determined and change on individual HAM-D items also was assessed. The magnitude of within-group change for the subscales and individual items was expressed as effect size (ES) and between-group significance tested with ANCOVA. The magnitude of change was also examined comparing the response rates f...

Aripiprazole: Hyperamylasaemia (first report) and hyperlipaseaemia: case report

Reactions — Tue, 15 Dec 2009 14:08:48 +0100

(Source: Reactions)

Aripiprazole: Catatonia: case report

Reactions — Tue, 15 Dec 2009 14:08:48 +0100

(Source: Reactions)

Effect of Aripiprazole on Cognition in the Treatment of Patients with Schizophrenia

Pharmacopsychiatry — Sat, 12 Dec 2009 16:09:42 +0100

PharmacopsychiatryDOI: 10.1055/s-0029-1239539Abstract The aim of this study was to assess the cognitive effects of aripiprazole in inpatients with schizophrenia.[...]© Georg Thieme Verlag KG Stuttgart · New YorkGet connected:Table of contents | Abstract | Full text (Source: Pharmacopsychiatry)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

FDA panel request stronger warnings about metabolic effects of aripiprazole (Abilify®) in children to be included in license

NeLM - Mental Health — Thu, 10 Dec 2009 00:00:00 +0100

Source: Reuters Health News Area: News An advisory panel to the FDA has voted unanimously that the current labelling for paediatric uses of aripiprazole (Abilify®) does not adequately warn of the risk of excessive weight gain. The panel recommended that FDA staff work on a revised label, which might include moving all information on metabolic effects of the drug in children to the warning section. Other metabolic effects could include development of type 2 diabetes or metabolic syndrome. (Source: NeLM - Mental Health)

Olanzapine/risperidone: Pisa syndrome and tardive dyskinesia, treated with aripiprazole: case report

Reactions — Mon, 07 Dec 2009 14:04:26 +0100

(Source: Reactions)

ABILIFY (Aripiprazole) Tablet ABILIFY (Aripiprazole) Solution ABILIFY (Aripiprazole) Tablet, Orally Disintegrating ABILIFY (Aripiprazole) Injection, Solution [Otsuka America Pharmaceuticals Inc]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 07 Dec 2009 05:00:00 +0100

Updated Date: Dec 7, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Treating bipolar disorder in the primary care setting: the role of aripiprazole.

Primary Care Companion to the Journal of Clinical Psychiatry — Sun, 06 Dec 2009 04:28:03 +0100

CONCLUSIONS: Accurate diagnosis and treatment of bipolar disorder are challenges increasingly faced by primary care physicians. Strategies geared toward detection, diagnosis, and management of bipolar I disorder and other bipolar spectrum disorders may improve the treatment outcome for patients. Aripiprazole may be considered as another first-line choice for the treatment of bipolar I disorder; however, its utility in patients with bipolar spectrum disorders is yet to be determined. PMID: 19956463 [PubMed - in process] (Source: Primary Care Companion to the Journal of Clinical Psychiatry)

Aripiprazole Eases Irritability in Autistic Kids but Causes Weight Gain: Study

Medscape Med Students Headlines — Tue, 01 Dec 2009 16:57:57 +0100

The atypical antipsychotic agent aripiprazole (Abilify) reduced symptoms of irritability in children and adolescents with autism in an 8-week clinical trial, investigators report in the December issue of Pediatrics. Reuters Health Information (Source: Medscape Med Students Headlines)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Is Aripiprazole Useful to Refrain From Cocaine Use After Detoxification (Avoiding Relapses)?

Addictive Disorders & Their Treatment — Tue, 01 Dec 2009 00:00:00 +0100

Cocaine abuse/addiction is a recidivist, chronic disturbance and it represents a crucial issue of public health, because of physical and psychic disturbances, associated to the use of this substance. Nowadays, no specific drug has been approved by the Food and Drugs Administration for the treatment of cocaine addiction. In the treatment of cocaine abuse/addiction, both agonist dopaminergic drugs (ropinirole, amantadine, pergolide, and psychostimulants), and antagonist action drugs (traditional antipsychotics) have been proposed. Aripiprazole is an atypical antipsychotic, marketing in the USA since 2003 for the treatment of schizophrenia, mania, and mixed bipolar episodes, with peculiar pharmacologic properties in comparison with the other second generation's antipsychotics. Here we describ...

Aripiprazole Approved for Autism-Related Irritability

Clinical Psychiatry News — Tue, 01 Dec 2009 00:00:00 +0100

The Food and Drug Administration's approval of the atypical antipsychotic aripiprazole for the treatment of irritability associated with autistic disorder in children and adolescents aged 6–17 years provides physicians with one more option for this indication—which includes symptoms of aggression toward others, deliberate self-injuriousness, temper tantrums, and quickly changing moods. (Source: Clinical Psychiatry News)

Children on Atypical Antipsychotics Gain Weight: Study of 272 subjects shows link to lipid and glucose abnormalities as well as hypertension.

Clinical Endocrinology News — Tue, 01 Dec 2009 00:00:00 +0100

Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder

PEDIATRICS — Mon, 30 Nov 2009 12:01:58 +0100

CONCLUSIONS: Aripiprazole was efficacious in children and adolescents with irritability associated with autistic disorder and was generally safe and well tolerated. (Source: PEDIATRICS)

Abilify Treats Autism-Related Irritability

WebMD Health — Mon, 30 Nov 2009 05:00:00 +0100

The drug Abilify (aripiprazole) may help ease the symptoms of irritability related to autism in children and adolescents, a study shows. (Source: WebMD Health)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Behavioral, Drug Therapies Can Benefit Autistic Children

Modern Medicine — Mon, 30 Nov 2009 00:00:00 +0100

Children with autism may benefit from the Early Start Denver Model behavioral intervention or treatment with aripiprazole, according to two studies published online Nov. 30 in Pediatrics. (Source: Modern Medicine)

U.S. Food And Drug Administration Approves ABILIFY® (aripiprazole) For The Treatment Of Irritability Associated With Autistic Disorder In Patients

Health News from Medical News Today — Sat, 28 Nov 2009 08:00:00 +0100

(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced that the U.S. (Source: Health News from Medical News Today)

U.S. Food And Drug Administration Approves ABILIFY® (aripiprazole) For The Treatment Of Irritability Associated With Autistic Disorder In Patients

Pharma Industry News From Medical News Today — Sat, 28 Nov 2009 08:00:00 +0100

(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods. (Source: Pharma Industry News From Medical News Today)

U.S. Food And Drug Administration Approves ABILIFY® (aripiprazole) For The Treatment Of Irritability Associated With Autistic Disorder In Patients

Autism News From Medical News Today — Sat, 28 Nov 2009 08:00:00 +0100

(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced that the U.S... (Source: Autism News From Medical News Today)

Improvement in social competence in patients with schizophrenia: a pilot study using a performance-based measure using virtual reality

Human Psychopharmacology: Clinical and Experimental — Fri, 27 Nov 2009 00:00:00 +0100

The objective of this study was to explore the possibility of the use of Virtual Reality Functional Skills Assessment (VRFSA) in a future regular clinical trial, as well as to report a preliminary result about effectiveness of atypical antipsychotics to social competence in schizophrenia.We developed the VRFSA that measured subjects' performances automatically and used analogue scale rather than Likert scale. Twenty-four female patients with paranoid schizophrenia and 15 healthy females were recruited. This was a 6-week, randomized, open-label, and flexible dose study, and 2 treatments (baseline versus post-treatment) × 2 skills phases (receptive versus expressive) × 2 patient groups (aripiprazole versus risperidone) analysis of variance was used in the final analysis.There was a signifi...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

FDA Approves Aripiprazole to Treat Irritability in Autistic Children

Medscape Today Headlines — Wed, 25 Nov 2009 04:52:21 +0100

Aripiprazole therapy may improve symptoms of aggression, self-hurt, temper tantrums, and quickly changing moods. Medscape Medical News (Source: Medscape Today Headlines)

Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study

Psychiatry and Clinical Neurosciences — Wed, 25 Nov 2009 00:00:00 +0100

The purpose of the present study was to evaluate changes in metabolic parameters after switching to aripiprazole in Japanese population. In this 1-year observation study, following a switch to aripiprazole, 32 patients with schizophrenia were observed and assessment was done of bodyweight, total cholesterol, triglyceride, serum prolactin level, and corrected QT (QTc) interval. Significant reductions were observed in these parameters other than QTc interval. Given known detrimental metabolic and hormonal effects of some atypical antipsychotics, a switch to aripiprazole may warrant serious consideration also in Asian patients who suffer those side-effects. (Source: Psychiatry and Clinical Neurosciences)

Myxedema Coma Associated with Combination Aripiprazole and Sertraline Therapy (December).

The Annals of Pharmacotherapy — Tue, 24 Nov 2009 00:00:00 +0100

CONCLUSIONS: Due to the widespread use of psychotropic medications, clinicians should be reminded of the rare, yet life-threatening, occurrence of MC when treating patients, especially with combination therapies such as sertraline and aripiprazole. PMID: 19934393 [PubMed - as supplied by publisher] (Source: The Annals of Pharmacotherapy)

FDA OKs Abilify for Autism-linked Irritability

Drugs.com - Pharma News — Mon, 23 Nov 2009 12:30:32 +0100

From Associated Press (November 21, 2009) PRINCETON, N.J.--The U.S. Food and Drug Administration has approved top-selling Abilify as a treatment for autism-related irritability in children from the ages of 6 to 17, drug maker Bristol-Myers Squibb... (Source: Drugs.com - Pharma News)

U.S. Food and Drug Administration Approves Abilify (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years)

Drugs.com - New Drug Approvals — Mon, 23 Nov 2009 01:46:08 +0100

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Nov 20, 2009 - Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA)... (Source: Drugs.com - New Drug Approvals)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

US FDA approves aripiprazole (Abilify®) for the treatment of irritability associated with autistic disorder in paediatric patients

NeLM - Paediatrics — Mon, 23 Nov 2009 00:00:00 +0100

Source: PharmaLive Area: News According to PharmaLive, the US FDA has approved the supplemental New Drug Application (sNDA) for aripiprazole (Abilify®) for the treatment of irritability associated with autistic disorder in paediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods. Pharmacological treatment for paediatric patients with irritability associated with autistic disorder is indicated as part of a total treatment program that includes psychological, educational, and social interventions. If treatment is initiated, American Psychiatric Association (APA) consensus guidelines recommend routine assessment and monitoring of patients' weight, waist circumference, ...

Aripiprazole: Priapism: case report

Reactions — Sun, 22 Nov 2009 14:04:51 +0100

(Source: Reactions)

Otsuka Pharmaceutical Europe Ltd Withdraws Its Application For An Extension Of Indication For Abilify (aripiprazole), Europe

Health News from Medical News Today — Fri, 20 Nov 2009 08:00:00 +0100

Otsuka Pharmaceutical Europe Ltd Withdraws Its Application For An Extension Of Indication For Abilify (aripiprazole), Europe

Mental Health News From Medical News Today — Fri, 20 Nov 2009 08:00:00 +0100

The European Medicines Agency has been formally notified by Otsuka Pharmaceutical Europe Ltd of its decision to withdraw its application for an extension of indication for the centrally authorised medicine Abilify (aripiprazole) tablets, orodispersible tablets and oral solution. Abilify was expected to be used in the treatment of major depressive episodes, as adjunctive therapy, in patients who have had an inadequate response to previous treatment with antidepressants. (Source: Mental Health News From Medical News Today)

Otsuka Pharmaceutical Europe Ltd Withdraws Its Application For An Extension Of Indication For Abilify (aripiprazole), Europe

Schizophrenia News From Medical News Today — Fri, 20 Nov 2009 08:00:00 +0100

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Otsuka withdraws application for an extension of indication for aripiprazole (Abilify®) in EU

NeLM - Mental Health — Fri, 20 Nov 2009 00:00:00 +0100

Source: EMEA Area: News Otsuka Pharmaceutical Europe Ltd has informed the European Medicines of its decision to withdraw its application for an extension of indication for aripiprazole (Abilify®) tablets, orodispersible tablets and oral solution. The application had been for use in the treatment of major depressive episodes, as adjunctive therapy, in patients who have had an inadequate response to previous treatment with antidepressants. The drug is currently indicated for the treatment of schizophrenia and for the treatment and prevention of manic episodes in bipolar I disorder. The company stated that the withdrawal was based on the negative opinion from the Agency's advisory panel (CHMP) that the long-term data provided in support of the proposed indication were insufficient, as long-...

Effectiveness of Intramuscular Aripiprazole Injection in Patients with Catatonia: Report on Three Cases

Pharmacopsychiatry — Thu, 19 Nov 2009 16:36:21 +0100

Pharmacopsychiatry 2009; 42: 286-287DOI: 10.1055/s-0029-1224185© Georg Thieme Verlag KG Stuttgart · New YorkGet connected:Table of contents | Full text (Source: Pharmacopsychiatry)

Aripiprazole: Mania?: case report

Reactions — Mon, 16 Nov 2009 14:06:44 +0100

(Source: Reactions)

Aripiprazole/haloperidol/lithium: Movement disorders, polyuria and polydypsia, and Pisa syndrome after switching from haloperidol to aripiprazole: case report

Reactions — Mon, 16 Nov 2009 14:06:44 +0100

(Source: Reactions)

Aripiprazole/quetiapine: Urinary bladder rupture associated with fecaloma causing sudden death: case report

Reactions — Mon, 16 Nov 2009 14:06:44 +0100

(Source: Reactions)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Early Response to Aripiprazole May Predict Treatment Success in Adolescents With Schizophrenia

Medscape Medical News Headlines — Thu, 12 Nov 2009 17:07:38 +0100

This is the first study to confirm that, as in adults, the majority of response occurs early in adolescents with schizophrenia. Medscape Medical News (Source: Medscape Medical News Headlines)

Third Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?

Current Pharmaceutical Design — Thu, 12 Nov 2009 00:00:00 +0100

Authors: Mailman RB, Murthy V Functional selectivity is the term that describes drugs that cause markedly different signaling through a single receptor (e.g., full agonist at one pathway and antagonist at a second). It has been widely recognized recently that this phenomenon impacts the understanding of mechanism of action of some drugs, and has relevance to drug discovery. One of the clinical areas where this mechanism has particular importance is in the treatment of schizophrenia. Antipsychotic drugs have been grouped according to both pattern of clinical action and mechanism of action. The original antipsychotic drugs such as chlorpromazine and haloperidol have been called typical or first generation. They cause both antipsychotic actions and many side effects (extrapyramidal and en...

Risperidone: Tardive parkinsonism, treated with aripiprazole: case report

Reactions — Wed, 11 Nov 2009 14:08:04 +0100

(Source: Reactions)

Dopamine D(2)-D(3) receptor heteromers: pharmacological properties and therapeutic significance.

Current Opinion in Pharmacology — Thu, 05 Nov 2009 00:00:00 +0100

Authors: Maggio R, Millan MJ Heteromerization of dopamine receptors has been shown for both the D(1)/D(5) and D(2)/D(3)/D(4) receptor families, which couple positively and negatively, respectively, to adenylyl cyclase. The present article reviews data on dopamine heteromers formed by D(3), focusing in particular on associations with their D(2) counterparts. Certain antiparkinsonian agents, like the preferential and high efficacy D(3)>D(2) agonists, pramipexole, and ropinirole, show amplified potency at D(2)-D(3) heteromers versus constituent monomers. Accordingly, in cells cotransfected with D(2) and D(3) receptors, pramipexole, and ropinirole suppress forskolin (FK)-stimulated cAMP production with higher potencies as compared to cells transfected with D(2) or D(3) receptors only. F...

Methylphenidate Combined with Aripiprazole in Children and Adolescents with Bipolar Disorder and Attention-Deficit/Hyperactivity Disorder: A Randomized Crossover Trial

Journal of Child and Adolescent Psychopharmacology — Fri, 30 Oct 2009 22:58:11 +0100

Journal of Child and Adolescent Psychopharmacology Oct 2009, Vol. 19, No. 5: 553-561. (Source: Journal of Child and Adolescent Psychopharmacology)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Clozapine—Aripiprazole Association in a 7-Year-Old Girl with Schizophrenia: Clinical Efficacy and Successful Management of Neutropenia with Lithium

Journal of Child and Adolescent Psychopharmacology — Fri, 30 Oct 2009 22:58:03 +0100

Journal of Child and Adolescent Psychopharmacology Oct 2009, Vol. 19, No. 5: 595-598. (Source: Journal of Child and Adolescent Psychopharmacology)

Clozapine–Aripiprazole Association in a 7-Year-Old Girl with Schizophrenia: Clinical Efficacy and Successful Management of Neutropenia with Lithium

Journal of Child and Adolescent Psychopharmacology — Fri, 30 Oct 2009 22:58:03 +0100

Journal of Child and Adolescent Psychopharmacology Oct 2009, Vol. 19, No. 5: 595-598. (Source: Journal of Child and Adolescent Psychopharmacology)

Aripiprazole and Hypertension in Adolescents

Journal of Child and Adolescent Psychopharmacology — Fri, 30 Oct 2009 22:57:08 +0100

Journal of Child and Adolescent Psychopharmacology Oct 2009, Vol. 19, No. 5: 601-602. (Source: Journal of Child and Adolescent Psychopharmacology)

Cohort study: Cardiometabolic risk of second-generation antipsychotics during first-time use in children and adolescents

NeLM - Paediatrics — Wed, 28 Oct 2009 00:00:00 +0100

Source: JAMA Area: News The results of the SATIETY cohort study have shown that first-time second-generation antipsychotic medication (aripiprazole, olanzapine, quetiapine, or risperidone) use is associated with significant weight gain in paediatric and adolescent patients. The study was conducted between December 2001 and September 2007 at semi-urban, tertiary care, academic inpatient and outpatient clinics in New York. 338 youths aged 4 to 19 years with one week or less of antipsychotic medication exposure were enrolled (66.9%). Of these, 272 had at least one post baseline assessment (80.5%), and 205 patients completed the study (60.7%). Patients were treated for mood spectrum (n = 130; 47.8%), schizophrenia spectrum (n = 82; 30.1%), and disruptive or aggressive behaviour...

ORIGINAL CONTRIBUTION: Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents

JAMA — Tue, 27 Oct 2009 19:51:38 +0100

Conclusions First-time second-generation antipsychotic medication use was associated with significant weight gain with each medication. Metabolic changes varied among the 4 antipsychotic medications. (Source: JAMA)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Kids Are Gaining Weight on Medications Too

About.com Bipolar Disorder — Mon, 26 Oct 2009 00:00:00 +0100

This study tackles two issues - medication weight gain and research of side effects in children. During the study period of eleven weeks, the kids - each just starting treatment with an antipsychotic medication - gained 10 to 20 pounds. From what I've gathered, all 205 of the kids gained weight - 100% of them. Ouch! Why the weight gain with these meds? Researchers are not exactly sure, but believe it is probably related to increased appetite, changes in how the body metabolizes sugar and decreases in activity due to sedation. Tanner reports, "The study authors said their results show that children on the drugs should be closely monitored for weight gain and other side effects, and that when possible, other medicines should be tried first." My son took Abilify for several years. He also...

[Tics and Tourette's syndrome throughout the life span.]

Der Nervenarzt — Sun, 25 Oct 2009 00:00:00 +0100

Authors: Neuner I, Ludolph A Chronic motor and vocal tics lasting longer than a year are classified as Tourette's syndrome (TS). Tics mostly manifest before the age of 11 years. Boys are affected at a threefold higher rate than girls. Tics are often worst at the age of 14; in 50% of the cases the tic symptoms will remit nearly completely. Severely affected patients often suffer from comorbidities. In childhood and adolescence the most common comorbid condition is attention deficit hyperactivity disorder (ADHD). Obsessive-compulsive behaviour, anxiety and affective disorder might occur in the course of TS. A dysregulation in the dopaminergic neurotransmission in the cortico-striatal-thalamic-cortical circuits (CSTC) might be the underlying neurobiological basis. The psychotropic substan...

Dissociable Control of Impulsivity in Rats by Dopamine D2/3 Receptors in the Core and Shell Subregions of the Nucleus Accumbens

Neuropsychopharmacology — Tue, 20 Oct 2009 23:00:00 +0100

Dissociable Control of Impulsivity in Rats by Dopamine D2/3 Receptors in the Core and Shell Subregions of the Nucleus Accumbens Neuropsychopharmacology advance online publication, October 21, 2009. doi:10.1038/npp.2009.162 Authors: Morgane Besson, David Belin, Ruth McNamara, David EH Theobald, Aude Castel, Victoria L Beckett, Ben M Crittenden, Amy H Newman, Barry J Everitt, Trevor W Robbins & Jeffrey W Dalley Keywords: impulsivity, 5-CSRT task, NAcbs, DA receptors, nafadotride, aripiprazole (Source: Neuropsychopharmacology)

A Systematic Review of Cardiovascular Effects After Atypical Antipsychotic Medication Overdose

The Poison Review — Mon, 19 Oct 2009 20:44:30 +0100

2.5 out of 5 stars A SYSTEMATIC REVIEW OF CARDIOVASCULAR EFFECTS AFTER ATYPICAL ANTIPSYCHOTIC MEDICATION OVERDOSE. Tan HH et al. Amer J Emerg Med 2009;27:607-616. Abstract This is a review of cardiovascular effects reported in published cases of overdose from 5 atypical antipsychotic medications (AAPMs): aripiprazole (Abilify), olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal), and ziprasidone (Geodon). Although the results are skewed by publication bias and incomplete information, the authors interpret the data as suggesting that AAPM overdose is unlikely to cause significant cardiotoxicity. However, there were 13 deaths in the subgroup of 185 adult (> 16 yo) patients, some of whom arrested before an EKG or rhythm strip could be obtained. Thus, this paper d...

Aripiprazole versus other atypical antipsychotics for schizophrenia

NeLM - Drug Class Focused Reviews — Thu, 15 Oct 2009 23:00:00 +0100

Source: Cochrane Library Area: Evidence > Drug Class Focused Reviews Background In many countries of the industrialised world second generation (atypical) antipsychotics have become first line drug treatments for people with schizophrenia. The question as to whether, and if so how much, the effects of the various second generation antipsychotics differ is a matter of debate. In this review we examine how the efficacy and tolerability of aripiprazole differs from that of other second generation antipsychotics. Objectives To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. Search strategy We searched the Cochrane Schizophrenia Group Trials Register (March 2007) which is ba...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Antipsychotic effects on auditory sensory gating in schizophrenia patients

European Neuropsychopharmacology — Thu, 15 Oct 2009 00:00:00 +0100

Abstract: P50 sensory gating deficit has repeatedly been demonstrated in schizophrenia. Studies have produced inconsistent findings with respect to normalization of P50 gating in patients with schizophrenia receiving treatment with different antipsychotics. The current study was designed to determine whether there is a difference in P50 gating in schizophrenia patients treated with first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs), including clozapine. P50 evoked potential recordings were obtained from 160 patients with schizophrenia and 77 healthy comparison subjects. Forty-three patients were being treated with clozapine, sixty-eight were taking SGAs (33 risperidone, 21 olanzapine, 11 aripiprazole, and 3 combinations of SGAs) and 49 were being treated wit...

[Aripiprazole and acute dystonia.]

Tijdschrift voor Psychiatrie — Wed, 14 Oct 2009 15:10:02 +0100

Authors: Komen G, Van Den Eede F, Dom G The case of a patient who developed acute dystonia during treatment with aripiprazole prompted us to review the literature for reports on similar cases. From the literature we conclude that aripiprazole has a favourable profile as far as extrapyramidal side effects are concerned. However, the reports on extrapyramidal side effects in the literature may be incomplete. It is therefore still important that such cases are reported within the framework of post-marketing surveillance. PMID: 19821245 [PubMed - in process] (Source: Tijdschrift voor Psychiatrie)

Aripiprazole: Dystonia and akathisia: case report

Reactions — Mon, 12 Oct 2009 13:02:30 +0100

(Source: Reactions)

Aripiprazole: First report of acute myopia: case report

Reactions — Tue, 06 Oct 2009 16:33:26 +0100

(Source: Reactions)

The Brown University Psychopharmacology Update — Mon, 05 Oct 2009 19:00:47 +0100

Study Examines Impact of Treatment on Prodromal Symptom Progression in YouthTargeted Naltrexone Reduces Alcohol Use Among Male Problem DrinkersRhabdomyolysis After Clozapine and Lithium TreatmentMetabolic Assessment of Adjunctive Aripiprazole in MDDCognitive Effects of Lorazepam in APOE [epsiv]4 CarriersProdromal Treatment StudiesElevated Rate of Adverse Events With QuetiapineA Case of Myopathy Associated With Valproic AcidNew Approvals: Saphris (Asenapine) for Schizophrenia, Bipolar DisorderNew Approval: Intuniv (Guanfacine) for ADHD (Source: The Brown University Psychopharmacology Update)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapse

Psychopharmacology — Thu, 24 Sep 2009 16:41:33 +0100

Discussion These findings support the possibility that repeated aripiprazole may be an effective therapeutic agent for the prevention of relapse in abstinent cocaine users. Based on its antipsychotic profile, aripiprazole may be particularly useful for individuals diagnosed with comorbid psychoses, such as schizophrenia or bipolar disorder. Content Type Journal ArticleCategory Original InvestigationDOI 10.1007/s00213-009-1671-8Authors Matthew W. Feltenstein, Medical University of South Carolina Department of Neurosciences 173 Ashley Avenue Charleston SC 29425 USAPhong H. Do, Medical University of South Carolina Department of Neurosciences 173 Ashley Avenue Charleston SC 29425 USARonald E. See, Medical University of South Carolina Department of Neurosciences 173 Ashley...

Improvement in Pisa Syndrome and Tardive Dyskinesia Following Aripiprazole Treatment [LETTERS TO THE EDITOR]

J Neuropsychiatry Clin Neurosci — Tue, 22 Sep 2009 23:00:00 +0100

(Source: J Neuropsychiatry Clin Neurosci)

Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ).

CNS Neuroscience and Therapeutics — Sun, 20 Sep 2009 23:00:00 +0100

Authors: Chandler GM, Iosifescu DV, Pollack MH, Targum SD, Fava M The low rate of response to antidepressants in treatment resistant depression (TRD) justifies studies of next-step therapies following a treatment failure. In TRD clinical trials, it is important to verify the accurate diagnosis of treatment resistance for all enrolled subjects using a reliable and valid instrument. Self-rated scales can reduce the impact of investigator bias and reduce the time burden for clinical researchers. The Massachusetts General Hospital (MGH) Antidepressant Treatment Response Questionnaire (ATRQ) is a self-rated scale used to determine treatment resistance in major depressive disorder (MDD). The ADAPT-A study is a multi-center double-blind, placebo-controlled study of low-dose aripiprazole adjun...

Duration of Pharmacotherapy with Long-Acting Injectable Risperidone in the Treatment of Schizophrenia

Psychiatric Quarterly — Sat, 19 Sep 2009 05:52:43 +0100

Abstract Although long-acting injectable risperidone (LAIR) has been hypothesized to improve medication adherence compared to oral medications, data from real-world practice have yet to be presented on time to treatment discontinuation. Records of all new prescriptions for antipsychotic medication during the first 2 months of FY 2006 for VA patients diagnosed with schizophrenia (N = 11,821) were examined and duration of treatment with LAIR and oral antipsychotics were calculated for the next 2 years. Multivariable logistic regression was used to identify patient characteristics independently associated with receipt of LAIR. Proportional hazards models were used to compare the likelihood of discontinuing each of the medications as compared to LAIR. Altog...

Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity.

European Journal of Pharmacology — Mon, 14 Sep 2009 23:00:00 +0100

In conclusion, in selected rodent models for positive schizophrenia symptoms, ADX47273 showed better efficacy than LY354740. PMID: 19765575 [PubMed - as supplied by publisher] (Source: European Journal of Pharmacology)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Comparative Utility of Aripiprazole and Haloperidol in Schizophrenia: Post Hoc Analysis of Two 52-Week, Randomized, Controlled Trials

Applied Health Economics and Health Policy — Mon, 07 Sep 2009 17:33:56 +0100

(Source: Applied Health Economics and Health Policy)

Aripiprazole: Tardive dyskinesia and akathisia: case report

Reactions — Mon, 31 Aug 2009 12:03:34 +0100

(Source: Reactions)

The Mothers Act Disease Mongering Campaign - Part IV

NaturalNews.com — Thu, 27 Aug 2009 07:00:00 +0100

This article says Courtenay publishes a website about "postpartum depression among dads" called "www.saddaddy.com." However, when clicking on the saddaddy link, PostpartumMen comes up today.And surely by coincidence, Courtenay will soon have a new book for sale titled, "Sad Dads," which he is currently writing, according to his bio on the consulting firm's website."If you'd like to arrange an individual consultation with Dr. Courtenay, please call 415-346-6719," the PostpartumMen website states.And apparently postpartum depression in dads is catchy. "If you're experiencing PPND, it increases the likelihood that your partner is also depressed," Courtenay informs men on his website."It's important that she get help for herself as well," he kindly advises.He then provides a link to a page wit...

An Open-Label Study of Aripiprazole: Pharmacokinetics, Tolerability, and Effectiveness in Children and Adolescents with Conduct Disorder

Journal of Child and Adolescent Psychopharmacology — Mon, 24 Aug 2009 19:07:03 +0100

Journal of Child and Adolescent Psychopharmacology Aug 2009, Vol. 19, No. 4: 431-439. (Source: Journal of Child and Adolescent Psychopharmacology)

Open Label Aripiprazole in the Treatment of Youth with Tic Disorders

Journal of Child and Adolescent Psychopharmacology — Mon, 24 Aug 2009 19:04:28 +0100

Journal of Child and Adolescent Psychopharmacology Aug 2009, Vol. 19, No. 4: 441-447. (Source: Journal of Child and Adolescent Psychopharmacology)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

[A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists.]

Annales Pharmaceutiques Francaises — Mon, 24 Aug 2009 05:18:22 +0100

Authors: Costentin J Since chlorpromazine was described, antischizophrenic therapeutics have been enriched with various other D2 dopamine receptors antagonists, either neuroleptics (which develop extrapyramidal side effects) or non neuroleptic antipsychotics (devoid of extrapyramidal side effects when used at effective doses against psychotic expressions). The latter drugs display such properties on account of several associated pharmacological activities (D3 receptors antagonism more efficient than D2 antagonism; antagonism at cholinergic muscarinic receptors; antagonism at 5HT2 serotonin receptors). All these antipsychotic drugs are not, as initially described, neutral antagonists of D2 receptors, but are in fact inverse agonists (alpha<0), because they suppress the constitutive a...

Antipsychotics in pregnancy

Journal of Psychiatric and Mental Health Nursing — Sun, 23 Aug 2009 23:00:00 +0100

This article summarizes the literature relating to the use of antipsychotics in pregnancy with a focus on the most commonly used atypical antipsychotics. Discusses other key factors to be considered when using these medications in pregnant or lactating women. Recognizes the contribution of pregnancy registers in gathering data to provide guidance to clinicians about the psychopharmacological management of women with serious mental illness. Women who are pregnant and who have a history of psychosis are commonly managed with antipsychotic medications. The evidence regarding the use of antipsychotics in pregnancy has been insufficient to provide adequate support for this practice and is a concern for clinicians and women alike. This review presents literature surrounding the use of antipsycho...

Aripiprazole: Dose-Response Relationship in Schizophrenia and Schizoaffective Disorder

CNS Drugs — Fri, 21 Aug 2009 10:38:25 +0100

(Source: CNS Drugs)

[Diabetes and second-generation (atypical) antipsychotics.]

Annales d'Endocrinologie — Thu, 20 Aug 2009 23:00:00 +0100

Authors: Chabroux S, Haffen E, Penfornis A Schizophrenia is a common psychiatric illness (1% of the general population), characterized by the association of positive and negative symptoms and cognitive disorders. Antipsychotics, typical or atypical, are known to induce in patients with schizophrenia weight gain and abnormalities in glucose and lipid metabolisms. These modifications, in addition to metabolic risk factors, intrinsic to the psychiatric illness (physical inactivity, smoking, diabetes), increase the risk of cardiovascular complications. Some antipsychotics are associated with a higher risk of metabolic disorders. Before starting such a medication, all risk factors must be taken into account. In case of even effectiveness, one should consider the risk of inducing metabolic d...

Aripiprazole: Tardive dyskinesia: 2 case reports

Reactions — Mon, 17 Aug 2009 10:19:17 +0100

(Source: Reactions)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Evidence for the Partial Dopamine-Receptor Agonist Aripiprazole as a First-Line Treatment of Psychosis in Patients With Iatrogenic or Tumorogenic Hyperprolactinemia [REVIEW ARTICLES]

Psychosomatics — Sun, 16 Aug 2009 23:00:00 +0100

CONCLUSION: These findings suggest that aripiprazole may play an important niche role in treating psychotic patients sensitive to elevated prolactin and patients with prolactin-secreting pituitary tumors. (Source: Psychosomatics)

Tardive dyskinesia in a patient treated with quetiapine.

The World Journal of Biological Psychiatry — Fri, 14 Aug 2009 18:40:02 +0100

We report the case of a female patient with the diagnosis of schizoaffective disorder (using DSM-IV-TR criteria) who initially received amisulpride for 3 months, discontinued gradually because of persistent and distressing extra-pyramidal symptoms, and who developed tardive dyskinesia 3 months later after the initiation of quetiapine. A trial with ziprasidone resulted in a further worsening of tardive dyskinesia symptoms. A further trial with aripiprazole, improved her tardive dyskinesia symptoms. Although, it is under consideration the possibility that the improvement could have been due to the discontinuation of quetiapine, we conclude that aripiprazole improved the TD symptoms. PMID: 19673087 [PubMed - in process] (Source: The World Journal of Biological Psychiatry)

Using oral ziprasidone effectively: the food effect and dose-response.

Advances in Therapy — Fri, 07 Aug 2009 23:00:00 +0100

Authors: Citrome L Ziprasidone is a newer "atypical" or "secondgeneration" antipsychotic. Oral ziprasidone (zipras idone hydrochlor ide) has been approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia, and acute manic or mixed episodes associated with bipolar disorder (with or without psychotic features). Comparisons with other second-generation antipsychotics in meta-analyses reveal similar efficacy to that observed for quetiapine or aripiprazole, but inferior efficacy to that of olanzapine or risperidone in the treatment of schizophrenia. However, the rate of dose titration and the dose achieved may have an important bearing on ziprasidone's efficacy profile, with a target dose range of 120-160 mg/day being associated with optimal symptom control and...

ABILIFY (Aripiprazole) Tablet ABILIFY (Aripiprazole) Solution ABILIFY (Aripiprazole) Tablet, Orally Disintegrating ABILIFY (Aripiprazole) Injection, Solution [Otsuka America Pharmaceuticals Inc]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 07 Aug 2009 05:00:00 +0100

Updated Date: Aug 7, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder

Pharmacoepidemiology and Drug Safety — Wed, 05 Aug 2009 23:00:00 +0100

This study quantified the overall merit of adjunctive aripiprazole in major depressive disorder (MDD).Global benefit-risk (GBR) analysis quantified the benefit and risk differences between adjunctive aripiprazole and antidepressant (ADT) monotherapy. Three hundred and fifty six patients receiving ADT monotherapy and 366 patients receiving ADT and adjunctive aripiprazole (2-20 mg/day) were included. Efficacy measures included the Montgomery-Åsberg depression rating scale (MADRS) Total score response ([ge]50% reduction) and remission (response plus Total score [le] 10). Treatment-emergent adverse events were classified by severity. GBR ratio measures evaluated the relative benefit of adjunctive aripiprazole. Logistic regression models tested the effect of adjunctive aripiprazole on GBR and ...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Aripiprazole: Hiccups: case report

Reactions — Mon, 03 Aug 2009 10:55:12 +0100

(Source: Reactions)

Focus on Aripiprazole: A Review of its use in Child and Adolescent Psychiatry.

Journal of the Canadian Academy of Child and Adolescent Psychiatry — Fri, 31 Jul 2009 23:00:00 +0100

CONCLUSION: Aripiprazole may represent an important alternative for some children and adolescents who have experienced poor efficacy or significant metabolic adverse effects with their current antipsychotic treatment regimen. PMID: 19718428 [PubMed - in process] (Source: Journal of the Canadian Academy of Child and Adolescent Psychiatry)

Abilify (Aripiprazole) - updated on RxList

RxList - New and Updated Drug Monographs — Fri, 31 Jul 2009 07:00:00 +0100

Abilify (Aripiprazole) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)

Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder

Psychopharmacology — Thu, 30 Jul 2009 08:07:04 +0100

Conclusion The present study showed that addition of ARI to an SSRI regimen reverses the inhibitory action of the SSRI on monoaminergic neuronal firing. Content Type Journal ArticleCategory Original InvestigationDOI 10.1007/s00213-009-1611-7Authors Olga Chernoloz, University of Ottawa Institute of Mental Health Research 1145 Carling Avenue Ottawa ON K1Z 7K4 CanadaMostafa El Mansari, University of Ottawa Institute of Mental Health Research 1145 Carling Avenue Ottawa ON K1Z 7K4 CanadaPierre Blier, University of Ottawa Institute of Mental Health Research 1145 Carling Avenue Ottawa ON K1Z 7K4 Canada Journal PsychopharmacologyOnline ISSN 1432-2072Print ISSN 0033-3158 (Source: Psychopharmacology)

Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review

Annals of General Psychiatry — Sun, 26 Jul 2009 23:00:00 +0100

Conclusions: Aripiprazole appears effective for the treatment and prophylaxis against mania. The data on bipolar depression are so far negative, however there is a need for further study at lower dosages. The most frequent adverse effects are extrapyramidal signs and symptoms, especially akathisia, without any significant weight gain, hyperprolactinaemia or laboratory test changes. (Source: Annals of General Psychiatry)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Amisulpride/risperidone: Amenorrhoea and hyperprolactinaemia treated with aripiprazole: 2 case reports

Reactions — Sun, 26 Jul 2009 10:51:00 +0100

(Source: Reactions)

Abilify Has Made Strong Gains In Patient Share Across All Lines Of Therapy Since Last Year's Analysis Of Prescribing Trends In Schizophrenia

Health News from Medical News Today — Fri, 24 Jul 2009 08:00:00 +0100

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the patient share of Bristol-Myers Squibb/Otsuka's Abilify has grown in the first three lines of therapy since the 2008 analysis of prescribing trends in newly diagnosed schizophrenia patients. (Source: Health News from Medical News Today)

Treatment with aripiprazole and topiramate in an obese subject with borderline personality disorder, obsessive-compulsive symptoms and bulimia nervosa: a case report

Cases Journal — Wed, 22 Jul 2009 23:00:00 +0100

Conclusion: Co-administration of aripiprazole and topiramate could be a safe and effective long-term treatment for improving not only the symptoms of borderline personality disorder but also the associated health-related quality of life and interpersonal problems. (Source: Cases Journal)

Doctors, Meds & Friends

About.com Bipolar Disorder — Wed, 22 Jul 2009 23:00:00 +0100

I would like to introduce Zach. Zach is fourteen and just graduated from middle school. I sat down with him this week and talked to him about his diagnosis and medication. Zach has bipolar disorder and takes Abilify. Our conversation brought out a couple of great points from a teen's perspective. (Source: About.com Bipolar Disorder)

Chronic Motor Tic Disorder and Aripiprazole [LETTERS TO THE EDITOR]

J Neuropsychiatry Clin Neurosci — Mon, 20 Jul 2009 23:00:00 +0100

(Source: J Neuropsychiatry Clin Neurosci)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

The Mothers Act Disease Mongering Campaign - Part I

NaturalNews.com — Thu, 16 Jul 2009 07:00:00 +0100

(NaturalNews) The Mothers Act represents the ultimate example of disease mongering at its worst because the eight-year attempt to pass this federal legislation has evolved into profiteering never before exhibited so conspicuously.Disease mongering "is the selling of sickness that widens the boundaries of illness and grows the markets for those who sell and deliver treatments," according to Ray Moyniahan and David Henry in the April 11, 2006 paper in PLoS Med, titled, "The Fight against Disease Mongering." "It is exemplified most explicitly by many pharmaceutical industry -- funded disease-awareness campaigns -- more often designed to sell drugs than to illuminate or to inform or educate about the prevention of illness or the maintenance of health," the authors explain. "Drug companies are ...

A multiattribute decision model for bipolar disorder: identification of preferred mood-stabilizing medications.

The American Journal of Managed Care — Sat, 11 Jul 2009 18:12:03 +0100

CONCLUSION: The use of a MADM may be a beneficial tool to assist in making formulary or preferred therapeutic agent decisions. PMID: 19589006 [PubMed - as supplied by publisher] (Source: The American Journal of Managed Care)

Aripiprazole as an Adjunct to Clozapine Therapy in Adolescents with Early-onset Schizophrenia: A Retrospective Chart Review

Pharmacopsychiatry — Wed, 08 Jul 2009 12:29:01 +0100

Pharmacopsychiatry 2009; 42: 153-157DOI: 10.1055/s-0029-1202266Abstract Combination of antipsychotic substances is a therapeutic option increasingly applied in patients with schizophrenia, who do not respond to antipsychotic monotherapy. Recently, various reports on combination of clozapine with aripiprazole in adults have been published. As there is not yet data on adolescent patients, we aimed to study the above-mentioned augmentation strategy in this population.[...]© Georg Thieme Verlag KG Stuttgart · New YorkGet connected:Table of contents | Abstract | Full text (Source: Pharmacopsychiatry)

Aripiprazole for the Management of Olanzapine-induced Weight Gain

Pharmacopsychiatry — Wed, 08 Jul 2009 12:29:01 +0100

Pharmacopsychiatry 2009; 42: 166-167DOI: 10.1055/s-0029-1202262© Georg Thieme Verlag KG Stuttgart · New YorkGet connected:Table of contents | Full text (Source: Pharmacopsychiatry)

Aripiprazole overdose: Prolonged lethargy and tremor in a child: case report.

Reactions Weekly — Tue, 07 Jul 2009 10:50:55 +0100

Page: 9 (Source: Reactions Weekly)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Aripiprazole overdose: Prolonged lethargy and tremor in a child: case report

Reactions — Mon, 06 Jul 2009 10:49:38 +0100

(Source: Reactions)

The Brown University Psychopharmacology Update — Sun, 05 Jul 2009 12:21:57 +0100

Impact of Depression During Pregnancy vs Impact of TreatmentCANMAT and ISBD Release Updated Bipolar Disorder Guidelines for 2009Influence of Concurrent Drugs on Aripiprazole and Its MetaboliteMeta-Analysis Assesses Antidepressants for FibromyalgiaZiprasidone With Mood Stabilizer in Maintenance Treatment of Bipolar DisorderMethylphendiate Transdermal System in Adults With ADHDLurasidone for Acute SchizophreniaWisner et al. 2009 Study DetailsPediatric Bipolar DisorderZiprasidone for Medical Morbidity With Olanzapine or ClozapineQuetiapine Plus Citalopram for OCDHallucinations in the Context of Varenicline WithdrawalNew Drug: Fanapt for SchizophreniaNew Indication: Risperdal Consta for Bipolar I DisorderNew Formulation: Lamictal Orally Disintegrating Tablets (Source: The Brown University Psyc...

Aripiprazole Improved Social Measures in Schizophrenia

Clinical Psychiatry News — Tue, 30 Jun 2009 23:00:00 +0100

SAN FRANCISCO — Early episode schizophrenia responds better to aripiprazole than to haloperidol on measures of social engagement, a post hoc analysis of 460 patients presented in a poster session at the annual meeting of the American Psychiatric Association shows. (Source: Clinical Psychiatry News)

Aripiprazole for the Treatment of Agitation in Persons with Dementia?

Journal of the American Medical Directors Association — Mon, 29 Jun 2009 16:20:22 +0100

To the Editor: I was shocked to see in “Journal highlights” of the January 2009 issue of Caring for the Ages the apparent approval of aripiprazole for the “treatment” of agitation in persons with dementia referring to the Journal of the American Medical Directors Association article by Rappaport et al. The Food and Drug Administration (FDA) has issued a Black Box Warning: “Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death.” There is additional information from Dr. Sydney Wolfe's Web site: “In March 2005, the FDA revised the product package label of aripiprazole regarding an increased incidence of cerebrovascular side effects (stroke and transient ischemic attacks), including deaths, in aripiprazole-t...

Quantifying Risk: The Role of Absolute and Relative Measures in Interpreting Risk of Adverse Reactions from Product Labels of Antipsychotic Medications.

Current Drug Safety — Sat, 27 Jun 2009 15:20:12 +0100

In conclusion, with certain limitations, it is possible for the clinician to extract information from medication product labeling regarding the frequency with which certain adverse reactions can be expected. This supplements, but does not replace, information reported directly in clinical trial reports. PMID: 19534647 [PubMed - as supplied by publisher] (Source: Current Drug Safety)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Aripiprazole: Tardive dyskinesia: 2 case reports.

Reactions Weekly — Fri, 26 Jun 2009 14:16:20 +0100

Page: 9 (Source: Reactions Weekly)

Aripiprazole: Tardive dyskinesia: 2 case reports

Reactions — Thu, 25 Jun 2009 07:34:34 +0100

(Source: Reactions)

Effectiveness of second-generation antipsychotics with acute-phase schizophrenia

Schizophrenia Research — Wed, 24 Jun 2009 23:00:00 +0100

Conclusion: Olanzapine and risperidone are superior to quetiapine and aripiprazole for the acute treatment of psychosis in hospitalized patients. (Source: Schizophrenia Research)

Clinical Trials on Aripiprazole

Child and Adolescent Psychopharmacology News — Tue, 23 Jun 2009 23:00:00 +0100

Child and Adolescent Psychopharmacology News 13(6): 4-6 (Source: Child and Adolescent Psychopharmacology News)

MedWorm: Abilify

Clinical use of aripiprazole in patients with schizophrenia: A real-life setting results from the German Postmarketing Surveillance Study.

A Pilot, 15-month, randomised effectiveness trial of Risperidone long-acting injection (RLAI) versus oral atypical antipsychotic agents (AAP) in persons with bipolar disorder

Symptomatic Bradycardia with Oral Aripiprazole and Oral Ziprasidone (April).

Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors

Differential Effects of Various Typical and Atypical Antipsychotics on Plasma Glucose and Insulin Levels in the Mouse: Evidence for the Involvement of Sympathetic Regulation

Aripiprazole-induced rabbit syndrome: a case report

Aripiprazole for the maintenance treatment of bipolar I disorder: A review.

Aripiprazole in schizophrenia and schizoaffective disorder: A review.

The role of aripiprazole in Canada: A review of clinical and drug discontinuation data. Foreword.

Aripiprazole/risperidone: Parkinsonism: case report

Neurocognition and its influencing factors in the treatment of schizophrenia - effects of aripiprazole, olanzapine, quetiapine and risperidone

Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study

Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004

Aripiprazole: a drug with a novel mechanism of action and possible efficacy for alcohol dependence.

Favourable results in treatment-resistant schizophrenic patients under combination of aripiprazole with clozapine.

Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients.

Pathological gambling and compulsive eating associated with aripiprazole.

Aripiprazole effective in treatment of irritability in children with autism [HEALTH BRIEFS]

Treating Irritability in Children and Adolescents With Autism

Identification of Molecular Targets Associated With Ethanol Toxicity and Implications in Drug Development.

Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature

Effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in Japanese chronic schizophrenia

Aripiprazole in anorexia nervosa and low-weight bulimia nervosa: Case reports

Changes in Positive and Negative Syndrome Scale–Derived Hostility Factor in Adolescents with Schizophrenia Treated with Aripiprazole: Post Hoc Analysis of Randomized Clinical Trial Data

Predictors of Early Worsening after Switch to Aripiprazole: A Randomized, Controlled, Open-Label Study

Aripiprazole, Hypertension, and Confusion [LETTERS TO THE EDITOR]

Coping with Atypical Antipsychotic Side Effects

Alkermes Unveils Long-Acting Injectable Proprietary Platform For Treatment Of Schizophrenia And Other CNS Disorders

Cochrane review: Zotepine versus other atypical antipsychotics for schizophrenia

Cochrane review: Quetiapine versus other atypical antipsychotics for schizophrenia

Evidence-Based Use of Second-Generation Antipsychotics in a State Medicaid Pediatric Population, 2001-2005 [Articles]

Use of aripiprazole in clozapine induced enuresis: report of two cases.

Aripiprazole: Movement disorders: 6 case reports

Amisulpride versus other atypical antipsychotics for schizophrenia

The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior.

Identification of Selected Therapeutic Agents as Inhibitors of Carboxylesterase 1: Potential Sources of Metabolic Drug Interactions.

Trial of aripiprazole in the treatment of first-episode schizophrenia

Effectiveness of aripiprazole in a patient with presumed idiopathic Parkinson's disease and chronic paranoid schizophrenia

Aripiprazole: Paroxysmal supraventricular tachycardia: case report

Aripiprazole: Acute dystonia: case report

Risperidone: Hyperprolactinaemia attenuated with aripiprazole: case report

EMEA publishes questions and answers on the withdrawal of application for a change to the marketing authorisation for aripiprazole (AbilifyT)

The risk of death among adult participants in trials of antipsychotic drugs in schizophrenia1

Table of Contents

Metabolic Testing Rates in 3 State Medicaid Programs After FDA Warnings and ADA/APA Recommendations for Second-Generation Antipsychotic Drugs [Original Article]

Short Course of Atypicals Led to Rapid Weight Gain

Aripiprazole OK'd for Autism-Related Irritability

Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials [REVIEW ARTICLES]

Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis

Aripiprazole in Children and Adolescents with Tourette's Disorder: An Open-Label Safety and Tolerability Study

Co-operativity in agonist binding at the D2 dopamine receptor: evidence from agonist dissociation kinetics

The effect of dopamine partial agonists on the nicotine dependency in patients with schizophrenia

Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: A post-hoc, pooled analysis of two large, placebo-controlled studies

Aripiprazole: Hyperamylasaemia (first report) and hyperlipaseaemia: case report

Aripiprazole: Catatonia: case report

Effect of Aripiprazole on Cognition in the Treatment of Patients with Schizophrenia

FDA panel request stronger warnings about metabolic effects of aripiprazole (Abilify®) in children to be included in license

Olanzapine/risperidone: Pisa syndrome and tardive dyskinesia, treated with aripiprazole: case report

ABILIFY (Aripiprazole) Tablet ABILIFY (Aripiprazole) Solution ABILIFY (Aripiprazole) Tablet, Orally Disintegrating ABILIFY (Aripiprazole) Injection, Solution [Otsuka America Pharmaceuticals Inc]

Treating bipolar disorder in the primary care setting: the role of aripiprazole.

Aripiprazole Eases Irritability in Autistic Kids but Causes Weight Gain: Study

Is Aripiprazole Useful to Refrain From Cocaine Use After Detoxification (Avoiding Relapses)?

Aripiprazole Approved for Autism-Related Irritability

Children on Atypical Antipsychotics Gain Weight: Study of 272 subjects shows link to lipid and glucose abnormalities as well as hypertension.

Aripiprazole in the Treatment of Irritability in Children and Adolescents With Autistic Disorder

Abilify Treats Autism-Related Irritability

Behavioral, Drug Therapies Can Benefit Autistic Children

U.S. Food And Drug Administration Approves ABILIFY® (aripiprazole) For The Treatment Of Irritability Associated With Autistic Disorder In Patients

U.S. Food And Drug Administration Approves ABILIFY® (aripiprazole) For The Treatment Of Irritability Associated With Autistic Disorder In Patients

U.S. Food And Drug Administration Approves ABILIFY® (aripiprazole) For The Treatment Of Irritability Associated With Autistic Disorder In Patients

Improvement in social competence in patients with schizophrenia: a pilot study using a performance-based measure using virtual reality

FDA Approves Aripiprazole to Treat Irritability in Autistic Children

Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study

Myxedema Coma Associated with Combination Aripiprazole and Sertraline Therapy (December).

FDA OKs Abilify for Autism-linked Irritability

U.S. Food and Drug Administration Approves Abilify (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years)

US FDA approves aripiprazole (Abilify®) for the treatment of irritability associated with autistic disorder in paediatric patients

Aripiprazole: Priapism: case report

Otsuka Pharmaceutical Europe Ltd Withdraws Its Application For An Extension Of Indication For Abilify (aripiprazole), Europe